The FDA meeting is a binary catalyst on October 1, 2026. Traders should monitor for the outcome of the EOP2 meeting and any updates on the Phase 3 trial design. The recent dilutive capital raise at a discount overhangs the stock, and the company's history of poor post-filing performance warrants caution.
Price Chart
Executive Summary
Radiopharm Theranostics announced an End-of-Phase 2 meeting with the FDA scheduled for October 1, 2026, to align on a pivotal Phase 3 trial design for RAD101, a diagnostic imaging agent for recurrent brain metastases. The Phase 2b trial met its primary endpoint with 93% concordance with MRI. While this is a positive regulatory milestone for a pre-revenue biotech, the stock has a history of poor post-filing performance, and the company recently completed a dilutive capital raise at a ~26% discount, creating a mixed picture.
Key Facts
- Radiopharm scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to align on the design of a pivotal Phase 3 trial for RAD101.
- RAD101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint.
- The company is on track to be Phase 3 ready by year-end 2026.
- RAD101 has received FDA Fast Track Designation.
- The company recently completed a dilutive capital raise of approximately $4.05M via a registered direct offering at a ~26% discount to the last closing price, alongside an Australian Placement and Share Purchase Plan.
- The filing is incorporated by reference into the company's Form F-3 registration statement (File No. 333-292178).
Financial Impact
No financial figures reported in this filing. The company is pre-revenue with no disclosed financial data in this document.
Risk Factors
- The FDA may not align on the proposed Phase 3 trial design, potentially delaying the program.
- The company is pre-revenue and recently raised capital at a significant discount, indicating cash needs and potential further dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-090491 |
| Document: ea0302340-6k_radiopharm.htm | 0001213900-26-090491 |
| Document: 0001213900-26-090491-index-headers.html | 0001213900-26-090491 |
| Document: 0001213900-26-090491-index.html | 0001213900-26-090491 |
| Document: 0001213900-26-090491.txt | 0001213900-26-090491 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9960 (+0.61%) |
Oct 14, 2026 12d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9960 (−7.78%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9960 (−21.57%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9960 (−32.70%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9960 (−38.52%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9960 (+36.64%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9960 (−39.64%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9960 (−50.45%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9960 (−49.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers